BioSpace News Archive

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2023 financial results and provided a corporate update.

Anika Therapeutics, Inc. announced that the Company plans to issue its fourth quarter and year-end 2023 financial results after the close of the market on Wednesday, March 13, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI) today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided 2024 guidance.

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 44th Annual Cowen Health Care Conference, taking place March 4-6, 2024, in Boston, Massachusetts.

Terns Pharmaceuticals, Inc. announced that members of senior management will be participating in the following upcoming investor conferences in March.

Adults in the Ogden, Utah area with moderately to severely active ulcerative colitis (UC) may have the opportunity to join a research study assessing a new investigational medication.

G1 Therapeutics, Inc. today announced that G1’s Chief Executive Officer Jack Bailey will participate in a Breast & Lung Cancer Corporate Panel Discussion during the TD Cowen 44th Annual Health Care Conference on Wednesday March 6, 2024 at 9:10 AM EST.

IMUNON, Inc. (NASDAQ: IMNN) announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in patients with advanced ovarian cancer.

Sengenics Corporation LLC , a pioneer in the field of immunoproteomic biomarker discovery, proudly announces that it has entered into a sales distribution and services agreement with Chinese distributor Shanghai Universal Biotech Co., Ltd. (“UniV”).

Cannabis genetics company Phylos®, along with People Science, a direct-to-consumer scientific research and technology company, has conducted an IRB-approved, double-blind clinical research study on the effects of rare cannabinoid tetrahydrocannabivarin (THCV).